Effect of castor oil emulsion eyedrops on tear film composition and stability

Abstract Purpose An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid...

Full description

Saved in:

Bibliographic Details
Published in	Contact lens & anterior eye Vol. 33; no. 2; pp. 76 - 82
Main Authors	Maïssa, Cécile, Guillon, Michel, Simmons, Peter, Vehige, Joseph
Format	Journal Article
Language	English
Published	England Elsevier Ltd 01.04.2010
Subjects	Adult Aged Aged, 80 and over Castor oil Castor Oil - administration & dosage Dry eye Dry Eye Syndromes - diagnosis Dry Eye Syndromes - drug therapy Emulsions - administration & dosage Eyedrops Female Humans Male Middle Aged Ophthalmic Solutions - administration & dosage Ophthalmology Pilot Projects Tear film stability Tear lipids Tears - chemistry Treatment Outcome Triglycerides Eyedrops Tear film stability Triglycerides Tear lipids Dry eye Castor oil
Online Access	Get full text
ISSN	1367-0484 1476-5411 1476-5411
DOI	10.1016/j.clae.2009.10.005

Cover

Abstract	Abstract Purpose An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid layer. A secondary objective was to quantify the initial effects on ocular symptomatology. Methods The investigation was an open label pilot study on 5 normal and 10 dry eye subjects. A single eyedrop (Castor oil emulsion, Allergan) was instilled in each eye; the tear film appearance and composition were monitored for 4 h via in vivo visualisation using the Tearscope™ and post in vivo tear samples analysis by HPLC. Results Combined results for both normal and dry eye subjects showed that castor oil was detected up to 4 h after a single eyedrop instillation and associated with an increase in the level of tear film lipid. The relative amount of various lipid families was also changed. An increase in tear lipid layer thickness was significant up to one hour post-instillation for the symptomatic sub-population. The changes in tear film characteristics were associated with significantly lower symptoms up to four hours post-instillation for the symptomatic sub-population. Conclusion This pilot investigation showed that castor oil eyedrops achieved a residence time of at least four hours post-instillation, producing a more stable tear film and an associated significant decrease in ocular symptoms over the entire follow-up period for the symptomatic subjects.
AbstractList	Abstract Purpose An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid layer. A secondary objective was to quantify the initial effects on ocular symptomatology. Methods The investigation was an open label pilot study on 5 normal and 10 dry eye subjects. A single eyedrop (Castor oil emulsion, Allergan) was instilled in each eye; the tear film appearance and composition were monitored for 4 h via in vivo visualisation using the Tearscope™ and post in vivo tear samples analysis by HPLC. Results Combined results for both normal and dry eye subjects showed that castor oil was detected up to 4 h after a single eyedrop instillation and associated with an increase in the level of tear film lipid. The relative amount of various lipid families was also changed. An increase in tear lipid layer thickness was significant up to one hour post-instillation for the symptomatic sub-population. The changes in tear film characteristics were associated with significantly lower symptoms up to four hours post-instillation for the symptomatic sub-population. Conclusion This pilot investigation showed that castor oil eyedrops achieved a residence time of at least four hours post-instillation, producing a more stable tear film and an associated significant decrease in ocular symptoms over the entire follow-up period for the symptomatic subjects. An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid layer. A secondary objective was to quantify the initial effects on ocular symptomatology.PURPOSEAn emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid layer. A secondary objective was to quantify the initial effects on ocular symptomatology.The investigation was an open label pilot study on 5 normal and 10 dry eye subjects. A single eyedrop (Castor oil emulsion, Allergan) was instilled in each eye; the tear film appearance and composition were monitored for 4h via in vivo visualisation using the Tearscope and post in vivo tear samples analysis by HPLC.METHODSThe investigation was an open label pilot study on 5 normal and 10 dry eye subjects. A single eyedrop (Castor oil emulsion, Allergan) was instilled in each eye; the tear film appearance and composition were monitored for 4h via in vivo visualisation using the Tearscope and post in vivo tear samples analysis by HPLC.Combined results for both normal and dry eye subjects showed that castor oil was detected up to 4h after a single eyedrop instillation and associated with an increase in the level of tear film lipid. The relative amount of various lipid families was also changed. An increase in tear lipid layer thickness was significant up to one hour post-instillation for the symptomatic sub-population. The changes in tear film characteristics were associated with significantly lower symptoms up to four hours post-instillation for the symptomatic sub-population.RESULTSCombined results for both normal and dry eye subjects showed that castor oil was detected up to 4h after a single eyedrop instillation and associated with an increase in the level of tear film lipid. The relative amount of various lipid families was also changed. An increase in tear lipid layer thickness was significant up to one hour post-instillation for the symptomatic sub-population. The changes in tear film characteristics were associated with significantly lower symptoms up to four hours post-instillation for the symptomatic sub-population.This pilot investigation showed that castor oil eyedrops achieved a residence time of at least four hours post-instillation, producing a more stable tear film and an associated significant decrease in ocular symptoms over the entire follow-up period for the symptomatic subjects.CONCLUSIONThis pilot investigation showed that castor oil eyedrops achieved a residence time of at least four hours post-instillation, producing a more stable tear film and an associated significant decrease in ocular symptoms over the entire follow-up period for the symptomatic subjects. An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid layer. A secondary objective was to quantify the initial effects on ocular symptomatology. The investigation was an open label pilot study on 5 normal and 10 dry eye subjects. A single eyedrop (Castor oil emulsion, Allergan) was instilled in each eye; the tear film appearance and composition were monitored for 4 h via in vivo visualisation using the Tearscope™ and post in vivo tear samples analysis by HPLC. Combined results for both normal and dry eye subjects showed that castor oil was detected up to 4 h after a single eyedrop instillation and associated with an increase in the level of tear film lipid. The relative amount of various lipid families was also changed. An increase in tear lipid layer thickness was significant up to one hour post-instillation for the symptomatic sub-population. The changes in tear film characteristics were associated with significantly lower symptoms up to four hours post-instillation for the symptomatic sub-population. This pilot investigation showed that castor oil eyedrops achieved a residence time of at least four hours post-instillation, producing a more stable tear film and an associated significant decrease in ocular symptoms over the entire follow-up period for the symptomatic subjects. An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this investigation were to measure the prevalence of castor oil in the tear fluid over time and quantify the effects on the lipid layer. A secondary objective was to quantify the initial effects on ocular symptomatology. The investigation was an open label pilot study on 5 normal and 10 dry eye subjects. A single eyedrop (Castor oil emulsion, Allergan) was instilled in each eye; the tear film appearance and composition were monitored for 4h via in vivo visualisation using the Tearscope and post in vivo tear samples analysis by HPLC. Combined results for both normal and dry eye subjects showed that castor oil was detected up to 4h after a single eyedrop instillation and associated with an increase in the level of tear film lipid. The relative amount of various lipid families was also changed. An increase in tear lipid layer thickness was significant up to one hour post-instillation for the symptomatic sub-population. The changes in tear film characteristics were associated with significantly lower symptoms up to four hours post-instillation for the symptomatic sub-population. This pilot investigation showed that castor oil eyedrops achieved a residence time of at least four hours post-instillation, producing a more stable tear film and an associated significant decrease in ocular symptoms over the entire follow-up period for the symptomatic subjects.
Author	Maïssa, Cécile Vehige, Joseph Guillon, Michel Simmons, Peter
Author_xml	– sequence: 1 fullname: Maïssa, Cécile – sequence: 2 fullname: Guillon, Michel – sequence: 3 fullname: Simmons, Peter – sequence: 4 fullname: Vehige, Joseph
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/19963428$$D View this record in MEDLINE/PubMed
BookMark	eNp9kk1LxDAQhoMofv8BD5Kbp65Jk82mIIIsfoHiQe8hTaeQNW3WJBX235uwiuDBU4bhfcLwzByh3dGPgNAZJTNKqLhczYzTMKsJaXJjRsh8Bx1SvhDVnFO6m2smFhXhkh-goxhXJENNQ_bRAW0awXgtD9Hzbd-DSdj32OiYfMDeOgzD5KL1I4YNdMGvI851Ah1wb92AjR_WPtpUEnrscEy6tc6mzQna67WLcPr9HqO3u9u35UP19HL_uLx5qkyeLlWNkJKB4LVoqez7VkjDQNdSaOC0nVMBQrJaGiKE7DgVHWgiqeFlaMlrdowutt-ug_-YICY12GjAOT2Cn6JaMMZkIwXJyfPv5NQO0Kl1sIMOG_UjIAfqbcAEH2OA_jdCVLGsVqpYVsVy6WXLGZJ_IGOTLjpS0Nb9j15tUch6Pi0EFY2F0UBnQ96D6rz9H7_-gxtnR2u0e8-riis_hTGLV1TFWhH1Wi6gHABp8vLnZMG-AOTWq2Y
CitedBy_id	crossref_primary_10_1089_photob_2019_4788 crossref_primary_10_1089_photob_2020_4931 crossref_primary_10_4103_IJO_IJO_2987_22 crossref_primary_10_1155_2018_4691417 crossref_primary_10_1016_j_jtos_2017_05_006 crossref_primary_10_1080_02713683_2018_1437454 crossref_primary_10_1038_s41598_019_45475_7 crossref_primary_10_4103_jpbs_JPBS_338_20 crossref_primary_10_1016_j_ijpharm_2024_124783 crossref_primary_10_52711_0974_360X_2023_00452 crossref_primary_10_1089_jop_2017_0052 crossref_primary_10_1177_201010581202100104 crossref_primary_10_1016_j_cyto_2018_02_009 crossref_primary_10_1080_02713683_2018_1433860 crossref_primary_10_1016_j_jtos_2019_11_004 crossref_primary_10_1007_s11042_017_4438_y crossref_primary_10_3390_ph18010038 crossref_primary_10_3390_ijms24032758 crossref_primary_10_1016_j_clae_2015_07_003 crossref_primary_10_1016_j_jconrel_2013_06_030 crossref_primary_10_1016_j_jtos_2020_05_007 crossref_primary_10_1097_ICO_0b013e318269cb99 crossref_primary_10_52711_2321_5844_2023_00005 crossref_primary_10_1016_j_pharma_2011_01_001 crossref_primary_10_1080_15569527_2021_1973022 crossref_primary_10_1089_photob_2020_4953 crossref_primary_10_1167_tvst_10_4_21 crossref_primary_10_1016_j_clinthera_2015_01_001 crossref_primary_10_1016_j_hermed_2015_04_005 crossref_primary_10_3390_jcm10061289 crossref_primary_10_1208_s12249_024_02792_z crossref_primary_10_1016_j_ijpharm_2023_122622 crossref_primary_10_1016_j_jfo_2015_02_008 crossref_primary_10_3109_10837450_2013_769569 crossref_primary_10_1016_j_clae_2021_101449 crossref_primary_10_1080_13102818_2020_1838323 crossref_primary_10_1016_j_toxlet_2010_09_001 crossref_primary_10_1016_j_ejps_2025_107077 crossref_primary_10_1007_s40123_024_00885_3 crossref_primary_10_3390_pharmaceutics13010007 crossref_primary_10_1016_j_jtos_2017_03_005 crossref_primary_10_1089_photob_2021_0094 crossref_primary_10_1111_cxo_13148 crossref_primary_10_2478_acph_2019_0054 crossref_primary_10_2174_2210303113666230309151048 crossref_primary_10_1016_j_xphs_2023_12_015 crossref_primary_10_1097_OPX_0000000000000947 crossref_primary_10_1292_jvms_14_0143 crossref_primary_10_1111_aos_14252 crossref_primary_10_1097_OPX_0000000000000420 crossref_primary_10_1186_s12886_024_03390_0
Cites_doi	10.1167/iovs.04-0864 10.1097/00006324-200205000-00011 10.1097/00003226-199907000-00003 10.1016/S0161-6420(98)96016-X 10.1007/BF00404705 10.1007/BF02854841 10.1016/S0161-6420(02)01262-9 10.1001/archopht.118.9.1264 10.1097/01.opx.0000178060.45925.5d 10.1097/01.ico.0000244875.92879.1a 10.1016/S0161-6420(00)00035-X 10.1097/00006324-199708000-00023 10.1136/bjo.86.12.1347 10.1016/j.ophtha.2003.07.008 10.1016/S0161-6420(99)00176-1
ContentType	Journal Article
Copyright	British Contact Lens Association 2009 British Contact Lens Association 2009 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.
Copyright_xml	– notice: British Contact Lens Association – notice: 2009 British Contact Lens Association – notice: 2009 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.clae.2009.10.005
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1476-5411
EndPage	82
ExternalDocumentID	19963428 10_1016_j_clae_2009_10_005 S1367048409001507 1_s2_0_S1367048409001507
Genre	Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: Allergan Inc.
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29F 4.4 457 4G. 53G 5GY 5VS 6PF 7-5 71M 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXKI AAXUO ABBQC ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIUM ACJTP ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXBA AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OF- OPF OQ~ OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SEL SES SEW SNG SPCBC SSH SSZ T5K Z5R ~G- AAIAV ABLVK ABYKQ AISVY AJBFU EFLBG LCYCR NAHTW AATTM AAYWO AAYXX ACIEU ACVFH ADCNI AEUPX AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKYEP APXCP CITATION CGR CUY CVF ECM EFKBS EIF NPM 7X8
ID	FETCH-LOGICAL-c476t-96883e6426b18ffb68c3ea286ae41b516e68328c0668d416dea081c496348423
IEDL.DBID	AIKHN
ISSN	1367-0484 1476-5411
IngestDate	Thu Sep 04 16:45:49 EDT 2025 Mon Jul 21 06:04:07 EDT 2025 Tue Jul 01 00:41:52 EDT 2025 Thu Apr 24 23:11:29 EDT 2025 Fri Feb 23 02:28:35 EST 2024 Sun Feb 23 10:18:46 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Eyedrops Tear film stability Triglycerides Tear lipids Dry eye Castor oil
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 2009 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c476t-96883e6426b18ffb68c3ea286ae41b516e68328c0668d416dea081c496348423
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
PMID	19963428
PQID	733389860
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_733389860 pubmed_primary_19963428 crossref_primary_10_1016_j_clae_2009_10_005 crossref_citationtrail_10_1016_j_clae_2009_10_005 elsevier_sciencedirect_doi_10_1016_j_clae_2009_10_005 elsevier_clinicalkeyesjournals_1_s2_0_S1367048409001507
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2010-04-01
PublicationDateYYYYMMDD	2010-04-01
PublicationDate_xml	– month: 04 year: 2010 text: 2010-04-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Contact lens & anterior eye
PublicationTitleAlternate	Cont Lens Anterior Eye
PublicationYear	2010
Publisher	Elsevier Ltd
Publisher_xml	– name: Elsevier Ltd
References	Stevenson, Tauber, Reis (bib17) 2000; 107 Shimmura, Shimazaki, Tsubota (bib5) 1999; 18 Lekhanont, Rojanaporn, Chuck, Vongthongsri (bib9) 2006; 25 Goto, Shimazaki, Monden, Takano, Yagi (bib21) 2002; 109 Bailey, Bullimore, Raasch, Taylor (bib25) 1991; 32 Vehige, Carlisle, Felix, Simmons, Stoecker (bib18) 2003; 44 Bandeen-Roche, Muñoz, Tielsch, West, Schein (bib4) 1997; 38 Du toit, Pritchard, Heffernan, Simpson, Fonn (bib24) 2002; 79 Doughty, Fonn, Richter, Simpson T., Caffery, Gordon (bib3) 1997; 74 Lin, Cheng, Hsu, Tsai, Lin, Liu (bib8) 2005; 46 Lemp (bib14) 2008; 14 Lee, Lee, Saw, Gazzard, Koh, Widjaja (bib7) 2002; 86 Sall, Stevenson, Mundorf, Reis (bib16) 2000; 107 Moss, Klein, Klein (bib6) 2000; 118 Guillon, Guillon (bib23) 1994; 21 Di Pascuale, Goto, Tseng (bib19) 2004; 111 Lemp (bib1) 1995; 21 Khanal, Tomlinson, Pearce (bib20) 2005; 46 Nelson, Helms, Fiscella, Southwell, Hirsch (bib12) 2000; 17 McCarty, Bansal, Livingston, Stanislavsky, Taylor (bib10) 1998; 105 Guillon, Allary, Guillon, Orsborn (bib22) 1992; 19 American Academy of Ophthalmology (bib13) 2006 Hom, Simmons (bib15) 2003 Hikichi, Yoshida, Fukui, Hamano, Ri, Araki (bib2) 1995; 233 Guillon, Maissa (bib11) 2005; 82 American Academy of Ophthalmology (10.1016/j.clae.2009.10.005_bib13) 2006 Nelson (10.1016/j.clae.2009.10.005_bib12) 2000; 17 Lemp (10.1016/j.clae.2009.10.005_bib1) 1995; 21 Guillon (10.1016/j.clae.2009.10.005_bib22) 1992; 19 Bandeen-Roche (10.1016/j.clae.2009.10.005_bib4) 1997; 38 Guillon (10.1016/j.clae.2009.10.005_bib11) 2005; 82 Lemp (10.1016/j.clae.2009.10.005_bib14) 2008; 14 Moss (10.1016/j.clae.2009.10.005_bib6) 2000; 118 Khanal (10.1016/j.clae.2009.10.005_bib20) 2005; 46 Di Pascuale (10.1016/j.clae.2009.10.005_bib19) 2004; 111 Bailey (10.1016/j.clae.2009.10.005_bib25) 1991; 32 Shimmura (10.1016/j.clae.2009.10.005_bib5) 1999; 18 Lin (10.1016/j.clae.2009.10.005_bib8) 2005; 46 Doughty (10.1016/j.clae.2009.10.005_bib3) 1997; 74 Lee (10.1016/j.clae.2009.10.005_bib7) 2002; 86 Hom (10.1016/j.clae.2009.10.005_bib15) 2003 Du toit (10.1016/j.clae.2009.10.005_bib24) 2002; 79 McCarty (10.1016/j.clae.2009.10.005_bib10) 1998; 105 Hikichi (10.1016/j.clae.2009.10.005_bib2) 1995; 233 Vehige (10.1016/j.clae.2009.10.005_bib18) 2003; 44 Guillon (10.1016/j.clae.2009.10.005_bib23) 1994; 21 Lekhanont (10.1016/j.clae.2009.10.005_bib9) 2006; 25 Stevenson (10.1016/j.clae.2009.10.005_bib17) 2000; 107 Sall (10.1016/j.clae.2009.10.005_bib16) 2000; 107 Goto (10.1016/j.clae.2009.10.005_bib21) 2002; 109
References_xml	– volume: 19 start-page: 104 year: 1992 end-page: 120 ident: bib22 article-title: Clinical management of regular replacement. Part 1. Selection of replacement frequency publication-title: ICLC – volume: 74 start-page: 624 year: 1997 end-page: 631 ident: bib3 article-title: A patient questionnaire approach of dry eye symptoms in patients presenting to optometric practices across Canada publication-title: Optom Vis Sci – volume: 46 start-page: 1593 year: 2005 end-page: 1598 ident: bib8 article-title: Association between symptoms and signs of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study publication-title: Invest Ophthalmol Vis Sci – volume: 105 start-page: 1114 year: 1998 end-page: 1119 ident: bib10 article-title: The epidemiology of dry eye in Melbourne, Australia publication-title: Ophthalmology – volume: 32 start-page: 422 year: 1991 end-page: 432 ident: bib25 article-title: Clinical grading and the effects of scaling publication-title: Invest Ophthalmol Vis Sci – volume: 107 start-page: 631 year: 2000 end-page: 639 ident: bib16 article-title: Two multi-center, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate or severe dry eye disease publication-title: Ophthalmology – volume: 17 start-page: 84 year: 2000 end-page: 93 ident: bib12 article-title: A new look at dry eye disease and its treatment publication-title: Adv Ther – volume: 118 start-page: 1264 year: 2000 end-page: 1268 ident: bib6 article-title: Prevalence and risk factors for dry eye syndrome publication-title: Arch Ophthalmol – start-page: 124 year: 2003 end-page: 126 ident: bib15 article-title: Understanding emulsion eyedrop technology publication-title: Rev Contact Lenses – volume: 79 start-page: 313 year: 2002 end-page: 320 ident: bib24 article-title: A comparison of three different scales for rating contact lens handling publication-title: Optom Vis Sci – volume: 233 start-page: 555 year: 1995 end-page: 558 ident: bib2 article-title: Prevalence of dry eye in Japanese eye centers publication-title: Graefes Arch Clin Exp Ophthalmol – volume: 38 start-page: 2469 year: 1997 end-page: 2475 ident: bib4 article-title: Self-reported assessment of dry eye in a population-based setting publication-title: Invest Ophthalmol Vis Sci – volume: 14 start-page: S88 year: 2008 end-page: S101 ident: bib14 article-title: Management of dry eye disease publication-title: Am J Manag Care – volume: 82 start-page: 829 year: 2005 end-page: 834 ident: bib11 article-title: Dry eye symptomatology of soft contact lens wearers and nonwearers publication-title: Optom Vis Sci – volume: 86 start-page: 1347 year: 2002 end-page: 1351 ident: bib7 article-title: Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia publication-title: Br J Ophthalmol – volume: 107 start-page: 967 year: 2000 end-page: 974 ident: bib17 article-title: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group publication-title: Ophthalmology – year: 2006 ident: bib13 article-title: State-of-the-art management of chronic dry eye: proceedings from a scientific roundtable – volume: 44 start-page: 2449 year: 2003 ident: bib18 article-title: Clinical trial results of a new emulsion-based dry eye treatment publication-title: Invest Ophthalmol Vis Sci – volume: 109 start-page: 2030 year: 2002 end-page: 2035 ident: bib21 article-title: Low concentration homogenized castor oil eye drops for non inflamed obstructive meibomian gland dysfunction publication-title: Ophthalmology – volume: 111 start-page: 783 year: 2004 end-page: 791 ident: bib19 article-title: Sequential changes of lipid tear film after instillation of a single drop of a new emulsion eye drop in dry eye patients publication-title: Ophthalmology – volume: 18 start-page: 408 year: 1999 end-page: 411 ident: bib5 article-title: Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye publication-title: Cornea – volume: 25 start-page: 1162 year: 2006 end-page: 1167 ident: bib9 article-title: Prevalence of dry eye in Bangkok, Thailand publication-title: Cornea – volume: 21 start-page: 221 year: 1995 end-page: 232 ident: bib1 article-title: Report of the National Eye Institute/Industry Workshop on Clinical trials in dry eyes publication-title: CLAO J – volume: 46 start-page: 2038 year: 2005 ident: bib20 article-title: Efficacy of an emulsion eye drop in the management of mild to moderate dry eyes publication-title: Invest Ophthalmol Vis Sci – volume: 21 start-page: 453 year: 1994 end-page: 483 ident: bib23 article-title: The role of tears in contact lens performance and its measurement publication-title: Contact lens practice – volume: 14 start-page: S88 year: 2008 ident: 10.1016/j.clae.2009.10.005_bib14 article-title: Management of dry eye disease publication-title: Am J Manag Care – volume: 46 start-page: 1593 issue: 5 year: 2005 ident: 10.1016/j.clae.2009.10.005_bib8 article-title: Association between symptoms and signs of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.04-0864 – volume: 44 start-page: 2449 year: 2003 ident: 10.1016/j.clae.2009.10.005_bib18 article-title: Clinical trial results of a new emulsion-based dry eye treatment publication-title: Invest Ophthalmol Vis Sci – volume: 79 start-page: 313 year: 2002 ident: 10.1016/j.clae.2009.10.005_bib24 article-title: A comparison of three different scales for rating contact lens handling publication-title: Optom Vis Sci doi: 10.1097/00006324-200205000-00011 – volume: 18 start-page: 408 issue: 4 year: 1999 ident: 10.1016/j.clae.2009.10.005_bib5 article-title: Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye publication-title: Cornea doi: 10.1097/00003226-199907000-00003 – start-page: 124 year: 2003 ident: 10.1016/j.clae.2009.10.005_bib15 article-title: Understanding emulsion eyedrop technology publication-title: Rev Contact Lenses – volume: 38 start-page: 2469 issue: 12 year: 1997 ident: 10.1016/j.clae.2009.10.005_bib4 article-title: Self-reported assessment of dry eye in a population-based setting publication-title: Invest Ophthalmol Vis Sci – volume: 105 start-page: 1114 year: 1998 ident: 10.1016/j.clae.2009.10.005_bib10 article-title: The epidemiology of dry eye in Melbourne, Australia publication-title: Ophthalmology doi: 10.1016/S0161-6420(98)96016-X – volume: 233 start-page: 555 issue: 9 year: 1995 ident: 10.1016/j.clae.2009.10.005_bib2 article-title: Prevalence of dry eye in Japanese eye centers publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/BF00404705 – volume: 21 start-page: 221 issue: 4 year: 1995 ident: 10.1016/j.clae.2009.10.005_bib1 article-title: Report of the National Eye Institute/Industry Workshop on Clinical trials in dry eyes publication-title: CLAO J – volume: 17 start-page: 84 year: 2000 ident: 10.1016/j.clae.2009.10.005_bib12 article-title: A new look at dry eye disease and its treatment publication-title: Adv Ther doi: 10.1007/BF02854841 – volume: 32 start-page: 422 year: 1991 ident: 10.1016/j.clae.2009.10.005_bib25 article-title: Clinical grading and the effects of scaling publication-title: Invest Ophthalmol Vis Sci – year: 2006 ident: 10.1016/j.clae.2009.10.005_bib13 – volume: 109 start-page: 2030 issue: 11 year: 2002 ident: 10.1016/j.clae.2009.10.005_bib21 article-title: Low concentration homogenized castor oil eye drops for non inflamed obstructive meibomian gland dysfunction publication-title: Ophthalmology doi: 10.1016/S0161-6420(02)01262-9 – volume: 118 start-page: 1264 year: 2000 ident: 10.1016/j.clae.2009.10.005_bib6 article-title: Prevalence and risk factors for dry eye syndrome publication-title: Arch Ophthalmol doi: 10.1001/archopht.118.9.1264 – volume: 82 start-page: 829 issue: 9 year: 2005 ident: 10.1016/j.clae.2009.10.005_bib11 article-title: Dry eye symptomatology of soft contact lens wearers and nonwearers publication-title: Optom Vis Sci doi: 10.1097/01.opx.0000178060.45925.5d – volume: 25 start-page: 1162 issue: 10 year: 2006 ident: 10.1016/j.clae.2009.10.005_bib9 article-title: Prevalence of dry eye in Bangkok, Thailand publication-title: Cornea doi: 10.1097/01.ico.0000244875.92879.1a – volume: 107 start-page: 967 year: 2000 ident: 10.1016/j.clae.2009.10.005_bib17 article-title: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group publication-title: Ophthalmology doi: 10.1016/S0161-6420(00)00035-X – volume: 19 start-page: 104 year: 1992 ident: 10.1016/j.clae.2009.10.005_bib22 article-title: Clinical management of regular replacement. Part 1. Selection of replacement frequency publication-title: ICLC – volume: 74 start-page: 624 issue: 8 year: 1997 ident: 10.1016/j.clae.2009.10.005_bib3 article-title: A patient questionnaire approach of dry eye symptoms in patients presenting to optometric practices across Canada publication-title: Optom Vis Sci doi: 10.1097/00006324-199708000-00023 – volume: 86 start-page: 1347 issue: 12 year: 2002 ident: 10.1016/j.clae.2009.10.005_bib7 article-title: Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia publication-title: Br J Ophthalmol doi: 10.1136/bjo.86.12.1347 – volume: 111 start-page: 783 issue: 4 year: 2004 ident: 10.1016/j.clae.2009.10.005_bib19 article-title: Sequential changes of lipid tear film after instillation of a single drop of a new emulsion eye drop in dry eye patients publication-title: Ophthalmology doi: 10.1016/j.ophtha.2003.07.008 – volume: 21 start-page: 453 year: 1994 ident: 10.1016/j.clae.2009.10.005_bib23 article-title: The role of tears in contact lens performance and its measurement – volume: 46 start-page: 2038 year: 2005 ident: 10.1016/j.clae.2009.10.005_bib20 article-title: Efficacy of an emulsion eye drop in the management of mild to moderate dry eyes publication-title: Invest Ophthalmol Vis Sci – volume: 107 start-page: 631 year: 2000 ident: 10.1016/j.clae.2009.10.005_bib16 article-title: Two multi-center, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate or severe dry eye disease publication-title: Ophthalmology doi: 10.1016/S0161-6420(99)00176-1
SSID	ssj0016990
Score	2.0782156
Snippet	Abstract Purpose An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary... An emulsion eyedrop containing castor oil has been shown to modify the tear film lipid layer and increase tear film stability. The primary objectives of this...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	76
SubjectTerms	Adult Aged Aged, 80 and over Castor oil Castor Oil - administration & dosage Dry eye Dry Eye Syndromes - diagnosis Dry Eye Syndromes - drug therapy Emulsions - administration & dosage Eyedrops Female Humans Male Middle Aged Ophthalmic Solutions - administration & dosage Ophthalmology Pilot Projects Tear film stability Tear lipids Tears - chemistry Treatment Outcome Triglycerides
Title	Effect of castor oil emulsion eyedrops on tear film composition and stability
URI	https://www.clinicalkey.es/playcontent/1-s2.0-S1367048409001507 https://dx.doi.org/10.1016/j.clae.2009.10.005 https://www.ncbi.nlm.nih.gov/pubmed/19963428 https://www.proquest.com/docview/733389860
Volume	33
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFH_MDcSL-O38GDl4k7r1K02PYzimsl1U2C2kTQqT2g67Hbz4t_vSpBMRPXgroSHNy_v4pfm9F4Cr2E28JJS-42WBdAIqMkdI5jsUwSnFgJNkdbrYdEYnz8H9PJy3YNTkwmhapfX9xqfX3tq29K00-8vFov-oi42h_uEGpa6TF21Bx8Noz9rQGd49TGabwwQaxyZZGH2C7mBzZwzNK82FMmUra5JX-Ft8-g1_1nFovAe7FkCSofnGfWip4gC2p_aI_BCmph4xKTOSCk19JOUiJ-p1nev_YkS9K_lWLiuCz5rKS7JF_ko0sdyyt4goJEHIWJNm34_gaXz7NJo49s4EJw0iunJiypivcFNBE5dlWUJZ6ivhMSpU4CahSxVFG2YpIg0mEYxJJRAUpAHaIUrG84-hXZSFOgUS-mGUDTR7Q8RB6IpECp1XG6GPYINADbrgNoLiqa0nrq-1yHlDHHvhWrj6ostYt6Fwu3C96bM01TT-fDtq5M-bPFH0bKqyZlZxl1ceH_AfqtCFcNPzmzZxDBR_jkiaZeZoZvrsRBSqXFc88nEvHzOK0z4xy_81gVgLz2Nn_xz0HHYMJUHTgS6gvXpbq0tEOqukB1s3H27P6vMnF1_41g
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB51W2mXywr2AV1ePnBDUZvEcZwjQqBCH5ctEjfLSRypq5BUpD3w73cmdopWKzhwi6xYjsfz-Bx_Mwa4SPw0SKM89IKC5x4XuvB0LkNPIDgVGHDSok0Xmy_E5IHfP0aPPbjucmGIVul8v_Xprbd2LSMnzdF6tRr9pmJjqH-4QWnr5MWfYMDpUus-DK7uppPF7jBBJIlNFkafQB1c7oyleWWlNrZsZUvyit6KT2_hzzYO3e7DVwcg2ZX9xgPomeobfJ67I_LvMLf1iFldsEwT9ZHVq5KZp21J_8WYeTH5c71uGD4TlZcVq_KJEbHcsbeYrnKGkLElzb78gOXtzfJ64rk7E7yMx2LjJULK0OCmQqS-LIpUyCw0OpBCG-6nkS-MQBuWGSINmSMYy41GUJBxtEOUTBD-hH5VV-YIWBRGcTEm9oZOeOTrNNeUVxujj5BjbsZD8DtBqczVE6drLUrVEcf-KBIuXXSZUBsKdwiXuz5rW03j3bfjTv6qyxNFz2YaZ2aN8lUTqLH6TxWGEO16_qNNCgPFuyOybpkVmhmdnejK1NtGxSHu5RMpcNqHdvlfJ5CQ8AL564ODnsOXyXI-U7O7xfQY9iw9gahBJ9DfPG_NKaKeTXrmtPov9Kr6vA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+castor+oil+emulsion+eyedrops+on+tear+film+composition+and+stability&rft.jtitle=Contact+lens+%26+anterior+eye&rft.au=Ma%C3%AFssa%2C+C%C3%A9cile&rft.au=Guillon%2C+Michel&rft.au=Simmons%2C+Peter&rft.au=Vehige%2C+Joseph&rft.date=2010-04-01&rft.issn=1367-0484&rft.volume=33&rft.issue=2&rft.spage=76&rft.epage=82&rft_id=info:doi/10.1016%2Fj.clae.2009.10.005&rft.externalDBID=ECK1-s2.0-S1367048409001507&rft.externalDocID=1_s2_0_S1367048409001507
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F13670484%2FS1367048410X00029%2Fcov150h.gif